JP Morgan Chase’s INmune Bio INMB Stock Holding History

JP Morgan Chase’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$37.9K	Sell	33,245 -8,120	-20%	-$11.6K	﹤0.01%	6307
2025 Q4	$64.5K	Sell	41,365 -16,349	-28%	-$29.2K	﹤0.01%	6113
2025 Q3	$119K	Sell	57,714 -15,383	-21%	-$35.2K	﹤0.01%	5798
2025 Q2	$169K	Buy	73,097 +66,700	+1,043%	+$489K	﹤0.01%	5324
2025 Q1	$50K	Sell	6,397 -4,938	-44%	-$39.2K	﹤0.01%	5882
2024 Q4	$52.9K	Buy	11,335 +5,461	+93%	+$28.5K	﹤0.01%	5995
2024 Q3	$31.7K	Buy	5,874 +672	+13%	+$4.78K	﹤0.01%	6125
2024 Q2	$45.9K	Buy	+5,202	New	+$51.3K	﹤0.01%	5891
2024 Q1	–	Sell	-3,479	Closed	-$39.2K	–	7626
2023 Q4	$39.2K	Buy	+3,479	New	+$29.2K	﹤0.01%	6069
2020 Q3	–	Sell	-3	Closed	–	–	5613
2020 Q2	$0	Buy	+3	New	+$15	﹤0.01%	5522

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase's INMB Position: Q1 2026 in Review

JP Morgan Chase reduced its INmune Bio (INMB) stake by 20% in Q1 2026, selling an estimated $11.6K and leaving 33,245 shares worth $37.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6307.

JP Morgan Chase first reported a position in INMB in Q2 2020 and has held it in 10 quarters since. The position peaked at $169K in Q2 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

JP Morgan Chase held 33,245 shares of INmune Bio worth $37.9K as of Q1 2026.
JP Morgan Chase sold 8,120 INmune Bio shares in Q1 2026, an estimated $11.6K.
INmune Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6307 holding.
JP Morgan Chase first reported a position in INmune Bio in Q2 2020 and has held it in 10 quarters since.
JP Morgan Chase's INmune Bio position peaked at $169K in Q2 2025.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.